Management of optic neuritis as a clinically first event of multiple sclerosis

Current Opinion in Ophthalmology

Volumn 23, Issue 6, 2012, Pages 472-476

  Kale, Nilufer ^a  

^a Bakirkoy Prof Dr Mazhar Osman Research and Training Hospital for Psychiatry   (Turkey)

Author keywords

corticosteroids; demyelination; disease modifying treatments; multiple sclerosis; optic neuritis

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PLACEBO; PREDNISONE;

CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COLOR VISION DEFECT; DEMYELINATING OPTIC NEURITIS; DEMYELINATION; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG MEGADOSE; EVOKED VISUAL RESPONSE; EYE PAIN; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RISK; TREATMENT DURATION; VISUAL IMPAIRMENT;

GLUCOCORTICOIDS; HUMANS; MULTIPLE SCLEROSIS; OPTIC NEURITIS;

EID: 84867860641     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e328358b202     Document Type: Review

References (37)

1. Shams PN, Plant GT. Optic neuritis: a review. Int MS J 2009; 16:82-89.
2. Abou Zeid N, Bhatti MT. Acute inflammatory demyelinating optic neuritis: evidence-based visual and neurological considerations. Neurologist 2008; 14:207-223.
3. Beck RW, Gal RL. Treatment of acute optic neuritis: a summary of findings from the Optic Neuritis Treatment Trial. Arch Ophthalmol 2008; 126:994-995. (Pubitemid 352008387)
4. Brodsky M, Nazarian S, Orengo-Nania S, et al. Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65:727-732. (Pubitemid 351831450)
5. Balcer LJ. Optic neuritis. N Engl J Med 2006; 354:1273-1280.
6. Beck RW, Cleary PA, Optic Neuritis Study Group. Recovery from severe visual loss in optic neuritis. Arch Ophthalmol 1993; 111:300. (Pubitemid 23085960)
7. Beck RW, Cleary PA, Backlund JC, Optic Neuritis Study Group. The course of visual recovery after optic neuritis: experience of the Optic Neuritis Treatment Trial. Ophthalmology 1994; 101:1771-1778. (Pubitemid 24378857)
8. Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology 2008; 115:1079-1082.
9. Menon V, Saxena R, Misra R, Phuljhele S.Management of optic neuritis. Indian J Ophthalmol 2011; 59:117-122.
10. Keltner JL, Johnson CA, Cello KE, et al., Optic Neuritis Study Group. Visual field profile of optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial from baseline through 15 years. Arch Ophthalmol 2010; 128:330-337.
11. Keltner JL, Johnson CA, Spurr JO, Beck RW. Comparison of central and peripheral visual field properties in the Optic Neuritis Treatment Trial. Am J Ophthalmol 1999; 128:543-553. (Pubitemid 29528590)
12. Fang JP, Donahue SP, Lin RH. Global visual field involvement in acute unilateral optic neuritis. Am J Ophthalmol 1999; 128:554-565. (Pubitemid 29528591)
13. Trobe JD, Beck RW, Moke PS, Cleary PA. Contrast sensitivity and other vision tests in the Optic Neuritis Treatment Trial. Am J Ophthalmol 1996; 121:547-553. (Pubitemid 26135863)
14. Balcer LJ, Baier ML, Cohen JA, et al. Contrast letter acuity as a visual component for the multiple sclerosis functional composite. Neurology 2003; 61:1367-1373. (Pubitemid 37463372)
15. Dooley MC, Foroozan R. Optic neuritis. J Ophthalmic Vis Res 2010; 5:182-187.
16. Mamarabadi M, Razjouyan H, Mohammadi F, Moghaddasi M. Assessment of outcome predictors after first attack of optic neuritis. Can J Neurol Sci 2011; 38:887-895.
17. Swanton JK, Fernando KT, Dalton CM, et al. Early MRI in optic neuritis: the risk for disability. Neurology 2009; 72:542-550.
18. Chan WJ. Recent advances in optic neuritis related to multiple sclerosis. Acta Ophthalmol 2011; 90:203-209. doi: 10.1111/j.1755-3768.2011.02145.
19. Frohman E, Costello F, Zivadinov R, et al. Optical coherence tomography in multiple sclerosis. Lancet Neurol 2006; 5:853-863. (Pubitemid 44715820)
20. Costello F, Coupland S, Hodge W, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006; 59:963-969. (Pubitemid 43830928)
21. Beck RW, Gal RL. Treatment of acute optic neuritis: a summary of findings from the Optic Neuritis Treatment Trial. Arch Ophthalmol 2008; 126:994-995. (Pubitemid 352008387)
22. Optic Neuritis Study Group, The 5-year risk of MS after optic neuritis: experience of the Optic Neuritis Treatment Trial. Neurology 1997; 49:1404-1413.
23. Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev 2012:4.
24. Tselis A, Perumal J, Caon C, et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 2008; 15:1163-1167.
25. Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005; 64:804-810. (Pubitemid 40316316)
26. Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis Treatment of 10 patients. Neurology 2004; 63:1081-1083. (Pubitemid 39287920)
27. Keegan M, Pineda AA, McClelland RL, et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002; 58:143-146.
28. Roesner S, Appel R, Gbadamosi J, et al. Treatment of steroid-unresponsive optic neuritis with plasma exchange. Acta Neurol Scand 2012; 126:103-108. doi: 10.1111/j.1600-0404.2011.01612.x.
29. Atkins EJ, Drews-Botsch CD, Newman NJ, et al. Management of optic neuritis in Canada: survey of ophthalmologists and neurologists. Can J Neurol Sci 2008; 35:179-184. (Pubitemid 351831054)
30. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343:898-904.
31. O'Connor P, Kinkel RP, Kremenchutzky M. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria. Mult Scler 2009; 15:728-734.
32. The PRISMS (Prevention of Relapses and Disability by Interferon-b 1a Subcutaneously in Multiple Sclerosis Study) Group and University of British Columbia MS\MRI Analysis Group: PRISMS-4: Long term efficacy of interferon beta-1a in relapsing MS. Neurology 2001; 56:1628-1636.
33. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67:1242-1249. (Pubitemid 44563835)
34. Comi G, Martinelli V, Rodegher M, et al., PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:1503-1511.
35. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study (ETOMS). Lancet 2001; 357:1576-1582. (Pubitemid 32488815)
36. Tintoré M, Rovira A, R?́o J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006; 67:968-972. (Pubitemid 44454586)
37. Chan JW. Early diagnosis, monitoring, and treatment of optic neuritis. Neurologist 2012; 18:23-31.